Holen Sie sich die Stockscreener-App
6.16
7.92%
-0.53
Handel nachbörslich:
6.16
Schlusskurs vom Vortag:
$6.69
Offen:
$6.53
24-Stunden-Volumen:
1.12M
Relative Volume:
1.71
Marktkapitalisierung:
$403.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.95M
KGV:
-6.6957
EPS:
-0.92
Netto-Cashflow:
$-33.46M
1W Leistung:
-33.69%
1M Leistung:
-20.62%
6M Leistung:
-16.53%
1J Leistung:
+87.23%
1-Tages-Spanne:
$5.9622
$6.62
1-Wochen-Bereich:
$5.9622
$9.395
52-Wochen-Spanne:
$3.0499
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Firmenname
Larimar Therapeutics Inc
Sektor
Branche
Telefon
844-511-9056
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Vergleichen Sie LRMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| LRMR | 6.16 | 403.26M | 0 | -36.95M | -33.46M | -0.92 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-19 | Eingeleitet | Guggenheim | Buy |
| 2022-02-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-02-01 | Eingeleitet | William Blair | Outperform |
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
Larimar Therapeutics (NASDAQ:LRMR) Given "Buy" Rating at HC Wainwright - MarketBeat
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times
Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire
Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
(LRMR) Trading Signals - Stock Traders Daily
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com
Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com
When (LRMR) Moves Investors should Listen - Stock Traders Daily
What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN
Larimar Therapeutics Q3 2024 Financial Update - TipRanks
Larimar: Q3 Earnings Snapshot - CTPost
Larimar Therapeutics (NASDAQ:LRMR) Shares Gap UpHere's Why - MarketBeat
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire
(LRMR) Investment Analysis and Advice - Stock Traders Daily
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance
Larimar initiated with bullish view at Oppenheimer on lead drug - MSN
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga
Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha
Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat
(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Inc (LRMR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
An Analysis of Larimar Therapeutics Inc (LRMR)’s Potential Price Growth - Knox Daily
Larimar Therapeutics Inc (LRMR) Stock: A Year of Highs and Lows - The InvestChronicle
Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock - Simply Wall St
Technical analysis of Larimar Therapeutics Inc (LRMR) stock chart patterns - US Post News
Financial Metrics Unveiled: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Spotlight - The Dwinnex
Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha
How To Trade (LRMR) - Stock Traders Daily
Larimar Therapeutics Inc [LRMR] Shares Rise 3.66 % on Thursday - Knox Daily
Quarry LP Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Expected to Earn Q3 2024 Earnings of ($0.37) Per Share - MarketBeat
Anchoring Your Portfolio: Is LRMR Stock a Safe Harbor? - The InvestChronicle
Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):